Gross Margin: A company's total sales revenue minus its cost of goods sold, divided by the total sales revenue, expressed as a percentage. Calculated as: Gross Income / Total Revenues
Coherus Oncology, Inc. (CHRS) had Gross Margin of 67.24% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$42.17M |
|
$168.02M |
|
$13.81M |
|
$28.36M |
|
$223.31M |
|
$-181.13M |
|
$-1.99M |
|
$-183.12M |
|
$-183.12M |
|
$-183.12M |
|
$-183.12M |
|
$168.02M |
|
$-183.12M |
|
$-181.13M |
|
$-177.21M |
|
117.14M |
|
117.14M |
|
$1.43 |
|
$1.43 |
|
| Balance Sheet Financials | |
$206.71M |
|
$1.34M |
|
$51.64M |
|
$258.34M |
|
$140.39M |
|
$37.05M |
|
$56.94M |
|
$197.33M |
|
$61.01M |
|
$14.78M |
|
$61.01M |
|
121.16M |
|
| Cash Flow Statement Financials | |
$-138.51M |
|
$375.09M |
|
$-273.70M |
|
$126.25M |
|
$89.12M |
|
$-37.13M |
|
$16.97M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.47 |
|
-- |
|
-- |
|
0.38 |
|
0.61 |
|
|
Gross Margin |
67.24% |
-429.51% |
|
-429.51% |
|
-420.21% |
|
-434.23% |
|
398.43% |
|
$-138.51M |
|
-- |
|
-- |
|
-- |
|
0.16 |
|
4.36 |
|
2.29 |
|
159.41 |
|
-300.13% |
|
-1239.42% |
|
-70.88% |
|
-186.74% |
|
$0.50 |
|
$-1.18 |
|
$-1.18 |
|